FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting.
FOXO4 is implicated in redox signaling and cellular senescence, but its clinical applications and direct antioxidant effects are not yet validated in humans.
Where it sits
this study against the rest of the foxo4-dri (foxo4-d-retro-inverso) corpusSummary and findings
This review evaluates the role of FOXO4 as a redox-sensitive regulator in antioxidant defense and cellular senescence. It analyzes 89 publications, with 18 providing FOXO4-specific evidence. The review highlights the need for further validation of FOXO4's target-gene antioxidant program.
Abstract
(1) Background: Reactive oxygen species (ROS) act as physiological signaling mediators but contribute to oxidative damage, cellular dysfunction, and age-related disease when redox homeostasis fails. Forkhead box O4 (FOXO4) has emerged as a redox-sensitive regulator linking stress adaptation, antioxidant defense, and cellular senescence. This structured narrative review critically evaluates which redox- and aging-related conclusions are supported directly for FOXO4 and which remain inferred from other FOXO isoforms. (2) Methods: PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to May 2026; Google Scholar was used only for supplementary citation tracking and did not contribute a separate platform-level count. Of 420 records, 300 remained after deduplication, 110 full texts were assessed, and 89 publications were retained. FOXO4-related evidence was classified as directly FOXO4-specific (<i>n</i> = 18), FOXO-family/conserved (<i>n</i> = 24), or extrapolated predominantly from FOXO1/FOXO3/DAF-16 (<i>n</i> = 20); 27 contextual publications on redox biology, senescence, disease, and NRF2 were tracked separately. (3) Results: The strongest FOXO4-specific evidence supports three mechanistic axes: cysteine-dependent redox sensing, stress-regulated nuclear trafficking and coactivator engagement through transportin-1 and p300/CBP, and FOXO4-p53-mediated survival of senescent cells. By contrast, direct FOXO4 regulation of commonly cited antioxidant targets, including SOD2, catalase, sestrins, and GADD45, remains insufficiently demonstrated and is inferred mainly from FOXO3 or broader FOXO-family studies. FOXO4-DRI has shown senolytic activity in preclinical models, including vascular endothelium, but has not been clinically validated. (4) Conclusions: FOXO4 is a redox-responsive transcriptional regulator with well-supported roles in cysteine-based signaling and senescent-cell survival, whereas its target-gene-level antioxidant program remains incompletely resolved. Clinical translation of FOXO4-p53 disruption requires isoform- and tissue-specific validation, pharmacokinetic and delivery studies, long-term toxicology, and explicit assessment of p53-dependent tumor surveillance.
Background
This paper addresses the role of FOXO4 in redox signaling and its implications for cellular senescence and antioxidant defense. Prior studies have established FOXO4's involvement in stress adaptation and aging processes, but the specific mechanisms and clinical relevance require further exploration. Understanding FOXO4's function could provide insights into therapeutic strategies for age-related diseases.
Methods
The authors conducted a structured narrative review by searching databases such as PubMed/MEDLINE, Scopus, and Web of Science from inception to May 2026. A total of 420 records were identified, with 300 remaining after deduplication, and 110 full texts assessed, leading to 89 publications retained for analysis. Evidence was classified based on its specificity to FOXO4 or extrapolated from other FOXO isoforms.
Results
The review identifies three mechanistic axes of FOXO4: cysteine-dependent redox sensing, stress-regulated nuclear trafficking, and FOXO4-p53-mediated survival of senescent cells. However, the evidence for FOXO4's direct regulation of antioxidant targets is limited and primarily inferred from studies on other FOXO isoforms. FOXO4-DRI's senolytic activity is noted in preclinical models, but clinical validation is absent.
Interpretation
The findings suggest that while FOXO4 plays a significant role in redox signaling and cellular senescence, its clinical implications remain uncertain due to a lack of direct evidence in humans. The limited effect sizes and reliance on extrapolated data from other FOXO isoforms may confound the conclusions. Further research is necessary to establish the clinical relevance of FOXO4-targeted therapies.
Key findings
- n=420 records initially identified, n=300 after deduplication, n=110 full texts assessed, n=89 publications retained.
- FOXO4-specific evidence classified as <i>n</i> = 18, FOXO-family/conserved <i>n</i> = 24, extrapolated from FOXO1/FOXO3/DAF-16 <i>n</i> = 20.
- Direct FOXO4 regulation of antioxidant targets remains insufficiently demonstrated.
- FOXO4-DRI has shown senolytic activity in preclinical models, including vascular endothelium.
- Clinical validation of FOXO4-DRI has not been reported.
Limitations
- Review based on existing literature, no new experimental data.
- Clinical implications remain speculative without direct human studies.
- Limited evidence for direct FOXO4 regulation of antioxidant targets.